Patient experience CSL’s commitment is to elevate the Patient Experience in drug development by embedding patient insights and lived experience through patient-informed clinical development programs, and formalising plans to include representative populations. CSL’s Patient Experience commitment for FY2030: • Informed Product development: all of CSL’s therapeutic product development programs are informed by patient insights. • Representative Clinical Trials: Phase III clinical trials incorporate participants that are representative of the target indicated population. Designing clinical research for patients with patients Listening to the input of patients, their caregivers and research participants as CSL designs clinical studies is a key focus. CSL enrols participants who reflect the disease’s epidemiology to enable the scientific validity of clinical studies. After all, who knows what study outcomes will benefit a patient’s life better than people living with the same condition. Patient blood management – addressing a global health issue CSL has joined the Blood & Beyond initiative, an organisation that works to raise awareness about Patient Blood Management (PBM) and improve blood health globally. Under the Blood & Beyond banner, CSL and co-lead Bristol Myers Squibb will advocate for necessary changes through hosting events, running campaigns and publishing scientific materials, all geared towards achieving concrete PBM implementation in hospitals. Anaemia and iron deficiency are among the most common, yet underdiagnosed and mostly untreated, blood conditions – especially in women, children, the elderly and in those living with chronic diseases. By recognising these as serious global health issues, the Blood & Beyond initiative directly supports CSL’s mission to advance the widespread adoption of PBM. Blood & Beyond combines medical expertise, patient advocacy, health economics, hospital management and the pharmaceutical industry to increase the uptake of PBM practices and spread the word about PBM’s benefits. Blood & Beyond engages with policy and healthcare decision makers, governments and regional authorities to support adoption of PBM policies and laws that drive implementation. Health authorities, including the WHO, endorse an approach called patient blood management (PBM) to preserve and safeguard a patient’s own blood while promoting patient safety and empowerment. PBM seeks to improve surgical and medical patient outcomes by optimally managing and preserving a patient’s own blood. It has three basic aims: (1) to diagnose and appropriately correct anaemia and iron deficiency, (2) to minimise blood loss and bleeding and (3) to support the patient while appropriate treatment is initiated instead of reverting to blood transfusion. Patient Advisory Boards and Operational Protocol Walkthroughs. CSL reviews clinical study visits and procedures with potential participants and researchers before finalising protocol design. The aim is to create a feasible and meaningful study. CSL also embeds patient touchpoints in developing medicines and vaccines through a patient engagement strategy specific to each product. Remote Options for Clinical Study Participants. Study participant and clinical researcher feedback on study design helps identify procedures that can be conducted in the home or a location better suited to the needs of each participant. During FY2025, over half of the studies started by CSL included remote options for participants. Patient Representation Planning. For medicines and vaccines in development, CSL employs various strategies to align clinical studies participants to the demographics of the population that lives with the disease. Some of these strategies include choosing the clinical sites, the patient advocacy/support groups CSL partners with and the communities CSL speak to about the clinical studies. CSL’s work with patients, for patients, doesn’t stop with its clinical trial execution. CSL underpins these efforts with its steadfast support in industry and advocacy consortia working to advance patient-focused drug development and clinical study awareness and access. CSL holds leadership roles in PALADIN (Patient Advocacy Leaders and Drug Development Industry Network) and DTRA (Decentralised Trial Research Alliance). CSL’s team actively engages with groups like the Society for Clinical Research Sites (SCRS) and EUPATI (European Patient Academy on Therapeutic Innovation) to incorporate best practices in the patient-focused conduct of clinical studies. It is done with the goal of delivering the best medicines to the patients who wait for improved options. Benefits for Health Care Systems • Blood is preserved for situations when it’s most needed • The overall cost of care decreases • Quality metrics improve Benefits for Patients • Improved outcomes • Increased safety • Reduced risk of complications and infections Around the world, the overuse of allogenic blood products can worsen patient outcomes; waste precious supplies of blood products; and spend health care budgets inefficiently. Detect and manage anemia/iron deficiency 1 What Are the Three Pillars of PBM? 2 Minimise blood loss 3 Optimise patient tolerance for postoperative anemia 29 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3